Vosevi is an anti-HCV (Hepatitis C Virus) drug owned by Gilead Sciences Inc. It contains three active ingredients: Sofosbuvir, Velpatasvir, and Voxilaprevir. The drug was authorized for market use on July 18, 2017, and is available in tablet form for oral administration. Vosevi holds a total of 33 patents, none of which have expired as of now.
The generic versions of Vosevi may become available after December 1, 2037, when the last patent is set to expire. This date could be subject to change depending on the outcome of any legal disputes or patent challenges, which can be filed against Vosevi from July 18, 2021 onwards.
Vosevi is used for the treatment of adult patients with chronic HCV infection. These may include patients who have genotype 1a or 3 infection and have previously been treated with an HCV regimen containing Sofosbuvir but not an NS5A inhibitor. It is also used to treat patients with genotypes 1-6 who have been previously treated with an HCV regimen containing an NS5A inhibitor.
Vosevi holds 33 patents in total. The patents cover various aspects, including the composition and method of treating Hepatitis C Virus. Several of these patents are protected by Pediatric Exclusivity (PED), which extends their expiration dates. The last patent, titled 'Combination formulation of three antiviral compounds', is set to expire on December 1, 2037. Below are the details of the patents: